Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 9,944 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Clear all

Conditions: Urinary Tract Infections
Interventions: Computer-assisted treatment group, Usual care group; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Fresno, California • Oakland, California • San Francisco, California

Conditions: Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: HPV Infection, Preventive Health Services
Interventions: Physician Communication 2 Virtual (PCOM2-virtual), Physician Communication Standard (PCOM-standard); Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Wichita, Kansas

Conditions: Cardiovascular Disease, HIV Infection
Interventions: Lovaza, Placebo; Drug
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Human Immunodeficiency Virus
Interventions: PATH; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Ysidro, California

Conditions: Tuberculosis
Interventions: RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 2 Years and older
Enrollment: 8,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 17 more

Conditions: Malaria
Interventions: FMP012 with AS01B adjuvant system, P falciparum Controlled Human Malaria Infection (CHMI); Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: HIV Infections, Pregnancy
Interventions: Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 60 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Herpes Zoster, Vaccine-Preventable Diseases
Interventions: Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo; Biological · Drug
Lead sponsor: Beijing Luzhu Biotechnology Co., Ltd.; Other
Eligibility: 50 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Infection
Interventions: Feeding tube dwell time of 48 hours, Feeding tube dwell time of 7 day; Device
Lead sponsor: University of Florida; Other
Eligibility: 30 Weeks to 40 Weeks
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cross Infection, Pneumonia, Ventilator-associated, Catheter-related Infections, Infection Due to Indwelling Urinary Catheter, Surgical Wound Infection
Interventions: Chlorhexidine gluconate, Standard bathing; Drug · Other
Lead sponsor: Joshua Swan; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C, Opiate Dependence
Interventions: Hepatitis C educational video, Video; Behavioral · Other
Lead sponsor: Organization to Achieve Solutions in Substance Abuse (OASIS); Other
Eligibility: 18 Years to 90 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Antioch, California • Richmond, California • San Francisco, California

Conditions: Prosthetic Joint Infection, Debridement With Prosthesis Retention, Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Suture
Interventions: VICRYL™ Plus (Coated VICRYL™ Plus Antibacterial), Polydioxanone (PDS™ II ) Sterile Synthetic Absorbable Surgical Suture-Monofilament; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 89 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Glycovir, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Chronic Hepatitis C
Interventions: Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin; Drug · Biological
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 10
States / cities: Palo Alto, California • Stanford, California • New Haven, Connecticut + 7 more

Conditions: Wound Infection
Interventions: Vancomycin Powder; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 90 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Depression, HIV, AIDS
Interventions: Escitalopram, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uveitis, Anterior, Panuveitis
Interventions: Placebo, LX211; Drug
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 14
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 11 more

Conditions: Skin and Soft Tissue Infections, Hiv, Hepatitis C, Bloodstream Infection
Interventions: ASAP; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: HIV Infections, Chickenpox
Interventions: Varicella Virus Vaccine (Live); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 22
States / cities: Long Beach, California • Los Angeles, California • Torrance, California + 13 more

Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions: Hyperpolarized Xe129; Drug
Lead sponsor: Mario Castro, MD, MPH; Other
Eligibility: 3 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Wound Infection
Interventions: Cefazolin PostOperatively, Cefazolin Preoperatively; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: HIV/AIDS
Interventions: APPEAL; Behavioral
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Non-infectious Anterior Uveitis
Interventions: Tacrolimus ophthalmic solution; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Phoenix, Arizona • Miami, Florida • Waltham, Massachusetts + 3 more

Search by objective public record fields.

Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers

The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)

PCOM2 - The Physician Communication Intervention, Version 2.0

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

Peers Plus Mobile App for Treatment in HIV

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

Optimal Feeding Tube Dwell Time in VLBW Infants to Reduce Feeding Tube Contamination

Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit

A Video-Based HCV Curriculum for Drug Users

Antibiotic-coated Braided Suture Study

A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Vancomycin in Spine Surgery

SSRI Effects on Depression and Immunity in HIV/AIDS

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs

Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy

Positive Affect Promotion to Empower Optimal Adherence to HIV Therapy

Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis